Lund: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
=='''The Lund Lab: The Lymphocyte in Context'''== | =='''The Lund Lab: The Lymphocyte in Context'''== | ||
We are a lab in the Department of Cell and Developmental Biology with joint affiliations with Molecular Microbiology and Immunology and Biomedical Engineering. Our goal is to improve the efficacy of cancer immunotherapy through novel therapeutic strategies targeted at the physical microenvironment of the tumor, which we are learning is largely immunosuppressive. Strategies that relieve this immunosuppression may allow conventional immunotherapies to have more durable clinical responses. While, the ultimate goal is improving clinical outcome, our lab will importantly strive to develop a basic understanding for how the physical components of the tumor microenvironment, i.e. the matrix and endothelium, drive immune suppression and how the infiltrating lymphocytes feed back on their environment to perpetuate this suppression. Unlocking these local mechanisms of negative regulation in cancer will provide novel insight into how we can manipulate and target them therapeutically. | |||
Our group uses a multidisciplinary approach to understand how the tumor microenvironment directs and maintains immune function and employ a variety of tools including transgenic mouse models, intravital imaging, tissue engineering, model immunotherapies and clinical samples. All projects require close collaboration with clinicians, biomedical engineers, biomaterial and computational scientists and it is the integration of perspectives and tools from these various fields that allows us to explore the functional and spatio-temporal complexity of the tumor immune microenvironment in novel and creative ways. | Our group uses a multidisciplinary approach to understand how the tumor microenvironment directs and maintains immune function and employ a variety of tools including transgenic mouse models, intravital imaging, tissue engineering, model immunotherapies and clinical samples. All projects require close collaboration with clinicians, biomedical engineers, biomaterial and computational scientists and it is the integration of perspectives and tools from these various fields that allows us to explore the functional and spatio-temporal complexity of the tumor immune microenvironment in novel and creative ways. | ||
The Lund Lab will become operational in January 2014! | |||
[[Image:OHSU.png|500px|left]] | [[Image:OHSU.png|500px|left]] | ||
Revision as of 14:08, 14 October 2013
The Lund Lab: The Lymphocyte in Context
We are a lab in the Department of Cell and Developmental Biology with joint affiliations with Molecular Microbiology and Immunology and Biomedical Engineering. Our goal is to improve the efficacy of cancer immunotherapy through novel therapeutic strategies targeted at the physical microenvironment of the tumor, which we are learning is largely immunosuppressive. Strategies that relieve this immunosuppression may allow conventional immunotherapies to have more durable clinical responses. While, the ultimate goal is improving clinical outcome, our lab will importantly strive to develop a basic understanding for how the physical components of the tumor microenvironment, i.e. the matrix and endothelium, drive immune suppression and how the infiltrating lymphocytes feed back on their environment to perpetuate this suppression. Unlocking these local mechanisms of negative regulation in cancer will provide novel insight into how we can manipulate and target them therapeutically.
Our group uses a multidisciplinary approach to understand how the tumor microenvironment directs and maintains immune function and employ a variety of tools including transgenic mouse models, intravital imaging, tissue engineering, model immunotherapies and clinical samples. All projects require close collaboration with clinicians, biomedical engineers, biomaterial and computational scientists and it is the integration of perspectives and tools from these various fields that allows us to explore the functional and spatio-temporal complexity of the tumor immune microenvironment in novel and creative ways.
The Lund Lab will become operational in January 2014!
